Introduction 24
Cell encapsulation therapy is the delivery of a therapeutic substance using cells 25 encapsulated in a semipermeable membrane. It was originally investigated as a 26 method for providing chronic insulin delivery to treat diabetes without the need for 27 immunosuppression, using pancreatic islets encapsulated in a semipermeable 28 membrane [1] . As a treatment for diabetes, cell encapsulation therapy represents a 29 significant improvement over conventional treatments, such as repeated insulin 30 injections and transplantation of unencapsulated islets. As encapsulated pancreatic 31 islets are responsive to elevations in blood sugar levels, there is no need for 32 repeated insulin injections. The islets are also protected from immunorejection by the 33 encapsulation material, thus chronic immunosuppression, required following 34 implantation of unencapsulated islets, is not necessary. The semipermeable 35 encapsulation material is also permissive of the exchange of wastes and nutrients, 36 thus facilitating the survival and function of the encapsulated islets over long periods 37 post transplantation (figure 1). Thus, as a treatment for diabetes, cell encapsulation 38 therapy represents a significant improvement over current therapies. These benefits 39 are an example of the broader potential of cell encapsulation therapy as therapies for 40 other chronic diseases, of which there are few or no effective treatment options. 41 
42
Cell encapsulation therapies have also been developed as potential treatments for a 43 variety of neurological diseases. One of the reasons for this broad applicability is that 44 the encapsulated cells can be genetically manipulated to secrete practically any 45 therapeutic protein that the gene sequence is known for. These therapies are 46 particularly useful to deliver therapeutics that cannot be delivered systemically, such 47 as neurotrophins, which elicit significant side effects when delivered systemically and 48 have a short half-life [2, 3] . Neurotrophins are proteins that have significant survival 49 effects on neurons and have demonstrated potential in supporting neuronal 50 populations that degenerate in diseases such as Alzheimer's and Parkinson'swhich secrete a variety of neuroprotective substances including BDNF, nerve growth 163 factor (NGF), neurotrophin-3 (NT-3) and fibroblast growth factor (FGF), have also 164 been used in the context of stroke [45] . CP cells, encapsulated in alginate 165 microcapsules and implanted into the brain, showed protective effects against 166 ischemic insults in rats [46, 47] . 167 168 Glucagon-like peptide-1 (GLP-1) is another protein that exhibits neuroprotective and 169 neurotrophic activity and has anti-apoptotic effects on neurons [48, 49] . GLP-1 has 170 been tested successfully in animal models of traumatic brain injury, using devices 171 consisting of stem cells transfected to secrete GLP-1 encapsulated in alginate 172 microcapsules [49] [50] [51] . As yet this device has not been tested in clinical trials. 173
Another device is also currently being trialled in a Phase I/II clinical trial sponsored by 174 Cellmed/Biocompatibles [52] . This device consists of stem cells transfected to 175 secrete CM1, a proprietary version of GLP-1, which is also anti-apoptotic [53] . It is 176 designed to treat intracerebral haemorrhage, a severe form of stroke. As yet data has 177 not been published from this trial. 178 179
Epilepsy 180
Epilepsy is one of the most common neurological disorders, affecting over 50 million 181 people worldwide and accounting for 1% of the total global burden of disease [54] . 182
Whilst not all causes of epilepsy are currently understood, any insult that disturbs 183 neuronal function is an important risk factor, such as head trauma, genetic 184 abnormalities, infection and tumours [55] 
Huntington's Disease 209
Huntington's disease (HD) is a genetic neurodegenerative disease caused by the 210 expression of a mutant form of the protein huntingtin which has deleterious effects on 211 certain populations of neurons [64] . It is one of a group of diseases classified as 212 polyglutamine diseases, which are caused by an expansion of CAG repeats in gene 213 sequences, resulting in proteins that have an expanded stretch of glutamine in their 214 amino acid sequence. Neurons of the striatum are particularly affected, although 215 degeneration also occurs in the cortex and hippocampus and these losses also 216 contribute to the pathogenesis of the disease [65] [66] [67] . HD is one of the more common 217 genetic neurodegenerative disease, with a prevalence of 5-7 per 100,000 people
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Cells from the CP are another possible treatment for HD. In rats and non-human 246 primates with striatal lesions, CP cells encapsulated in poly-ornithine coated alginate 247 yielded significant increases in the volume of the striatum and performance in 248 behavioural tests [83] [84] [85] [86] . In both animal models only minor tissue reactions were 249 reported and the implants were well tolerated. Further work and optimisation of these 250 implants is required to achieve maximum clinical benefit but current work 251 demonstrates their potential to at least slow the disease course of HD. 252 Promising results from this clinical trial could potentially lead to the development of 374 cell encapsulation therapies to deliver VEGF, bypassing issues inherent with a pump-375 based catheter system. 376 377
Chronic Pain 378
Chronic pain is a serious medical problem for a significant number of patients who 379 cannot achieve adequate relief. Whilst an accurate definition is somewhat 380 controversial, it can be defined as pain that extends beyond the expected time frame 381 of healing. Chronic pain affects at least 116 million adults in the USA alone at a cost 382 of $560-635 billion annually [124] . Treatment of chronic pain commonly involves 383 systemic delivery of opioids but there are significant issues associated with these 384 drugs, especially when used over long periods of time. Insensitivity to their actions particularly suited to such treatment as it is a relatively contained environment and 536 therefore secreted neurotrophins will be somewhat concentrated where they are 537 most needed. These implants consist of CNTF secreting cells in a hollow fiber 538 membrane consisting of poly(ethersulfone) containing an internal scaffold of 539 poly(ethylene terephthalate) yarn, which promotes cell attachment [177, 178] . These 540 implants were tested in rats, dogs and rabbits and were effective in protecting 541 photoreceptors from degeneration and were well tolerated [178, 179] . A study in 542 rabbits showed that this implant is capable of continuous delivery of CNTF at 543 concentrations above therapeutic thresholds for up to one year [179] . 544 545 Following these successful trials in animals, a Phase I clinical trial of six months 546 duration was conducted to assess the safety and efficacy of these implants. This 547 study demonstrated that implants recovered from patients still secreted CNTF at 548 concentrations above those deemed to be therapeutic [180] . The implants were alsowell tolerated, with no systemic or ocular complications observed, with the exception 550 of a single choroidal detachment, which was deemed likely due to mechanical insults 551 sustained during surgery [180] . There were also indications that visual acuity was 552 improved in some patients, but interpretation of these results was hampered by 553 variability, a small sample size of ten patients and lack of adequate controls. Longer 554 term Phase II and a Phase II/III clinical trial are currently underway. A Phase II study, 555 sponsored by Neurotech Pharmaceuticals, was designed to assess the safety and 556 efficacy of their CNTF-producing NT-501 implant in patients with dry AMD over an 18 557 month follow-up period [181] . The NT-501 implant was also tested in a Phase II/III 558 trial in patients with RP, which aimed to assess the performance of these implants in 559 patients out to 2.5 years post implantation [182] . As yet no data has been published 560 from these studies [177] . 561 562
Future Directions and Conclusions 563
Significant progress has been made in the development of cell encapsulation 564 therapies as treatments for neurological conditions. However, further challenges still 565 exist before these therapies can be accepted into the clinic. Importantly, more data is 566 needed regarding the longevity of cell encapsulation therapies, as these are 567 designed to be chronic delivery methods. Of primary concern is that the implants are 568 safe, i.e., they can remain in the host for long periods of time without causing 569 adverse reactions. This necessitates that the encapsulation material must be stable 570 in vivo for extended periods, thus remaining biocompatible and protecting the 571 encapsulated tissue from immunorejection. Another important consideration is the 572 consistency of the encapsulation material produced using scaled-up manufacturing 573 techniques, which are required to produce sufficient numbers of devices for large 574 scale clinical trials or for clinical use. Consistency is very important in gaining 575 regulatory approval for use in clinical trials or in the clinic, as variations in the 576 composition or purity of the materials could potentially lead to devices that fail in vivo.This is particularly pertinent for alginate, as it is derived from algae, a natural product 578 that can contain high levels of contaminating proteins. If adequate purification is not 579 achieved, biocompatibility could be compromised, resulting in a foreign body reaction 580 post implantation and possible capsule destruction [183, 184] . However, using 581 current purification methods, millions of alginate capsules can be produced 582 consistently under good manufacturing practise standards. Additionally, newer 583 manufacturing technologies being developed could see the number of capsules able 584 to be produced increase tenfold. Therefore, alginate is considered a viable material 585 for large scale cell encapsulation therapy. Batch to batch variability is less of an issue 586 for other materials, such as cellulose sulphate, which has been used successfully as 587 part of a cell encapsulation therapy for pancreatic cancer in a Phase I/II clinical trial 588 [185, 186] . Cellulose sulphate can now be produced in large quantities under good 589 manufacturing practice, which is compatible with clinical use [187, 188] . 590 591 Longevity data is also important in the context of the encapsulated tissue. 592
Encapsulated cells must not proliferate within the encapsulation device to such a 593 degree that they compromise the integrity of the device, which could potentially 594 expose them to the immune system. The encapsulated cells must also be capable of 595 secreting therapeutics for an acceptable period of time, depending on the therapy in 596 question. Whilst there are still issues to resolve and more data to obtain, cell 597 encapsulation represents a promising treatment strategy against a number of chronic 598 diseases with limited or no treatment options currently available. Considering the 599 social and economic impact of these diseases, the scope of potential benefits to be 600 obtained from cell encapsulation therapies is large. 
